In recent years, the advent of anti-vascular endothelial growth factors (anti-VEGF) and triamcinolone for the treatment of exudative macular degeneration, retinal vein occlusion and diabetic macular edema has dramatically increased the amount of patient exposures [6, 7]. This evidence concerns the gene VEGFA and retinal vein occlusion.